Type I Photosensitizer Targeting G-Quadruplex RNA Elicits Augmented Immunity for Cancer Ablation.
Angew Chem Int Ed Engl
; 62(17): e202300162, 2023 04 17.
Article
em En
| MEDLINE
| ID: mdl-36856160
ABSTRACT
Typeâ
I photodynamic therapy (PDT) represents a promising treatment modality for tumors with intrinsic hypoxia. However, typeâ
I photosensitizers (PSs), especially ones with near infrared (NIR) absorption, are limited and their efficacy needs improvement via new targeting tactics. We develop a NIR typeâ
I PS by engineering acridinium derived donor-π-acceptor systems. The PS exhibits an exclusive typeâ
I PDT mechanism due to effective intersystem crossing and disfavored energy transfer to O2 , and shows selective binding to G-quadruplexes (G4s) via hydrogen bonds identified by a molecular docking study. Moreover, it enables fluorogenic detection of G4s and efficient O2 â
- production in hypoxic conditions, leading to immunogenic cell death and substantial variations of gene expression in RNA sequencing. Our strategy demonstrates augmented antitumor immunity for effective ablation of immunogenic cold tumor, highlighting its potential of RNA-targeted typeâ
I PDT in precision cancer therapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fotoquimioterapia
/
Nanopartículas
/
Quadruplex G
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Angew Chem Int Ed Engl
Ano de publicação:
2023
Tipo de documento:
Article